Search

Your search keyword '"Szamosi, S"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Szamosi, S" Remove constraint Author: "Szamosi, S"
111 results on '"Szamosi, S"'

Search Results

2. AB0237 EFFECTS OF ONE-YEAR TOFACITINIB THERAPY ON ANGIOGENIC BIOMARKERS IN RHEUMATOID ARTHRITIS

3. AB0062 ANGIOTENSIN CONVERTING ENZYME ACTIVITY IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS

8. POS0390 SIMULTANEOUS ASSESSMENT OF JOINT AND VASCULAR INFLAMMATION BY PET-CT IN TOFACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY

9. POS0043 PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY IN THE ASSESSMENT OF BONE MINERAL DENSITY IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS

10. POS0383 EFFECTS OF TOFACITINIB THERAPY ON ARGININE AND METHIONINE METABOLITES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS: A METABOLOMIC APPROACH

12. FRI0373 ASSOCIATIONS OF VASCULAR PATHOPHYSIOLOGY AND BONE METABOLISM IN ANTI-TNF- TREATED RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS

13. THU0181 SOLUBLE VASCULAR BIOMARKERS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: EFFECTS OF ONE-YEAR ANTI-TNF-Α THERAPY

15. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

18. Update of EULAR recommendations for the treatment of systemic sclerosis

19. P173 Complex assessment of bone mineral density, fracture risk, vitamin D status and bone metabolism in hungarian systemic sclerosis patients

21. Update of EULAR recommendations for the treatment of systemic sclerosis

26. OP0272 Effects of Anti-TNF Therapy on Markers of Bone Homeostasis in Rheumatoid Arthritis and Ankylosing Spondylitis

34. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis

35. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

36. Fatigue and depression influence the prevalence of anxiety in patients with multiple sclerosis.

37. Can we define difficult-to-treat systemic sclerosis?

38. The 7-year follow-up of the Hungarian BICAMS validation cohort implies that cognitive performance may improve in multiple sclerosis patients.

40. Granulomatosis with polyangiitis or its mimic? A case report.

41. Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology.

42. Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals.

43. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis.

44. Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis.

45. [Diagnostic value of 18F-FDG PET/CT in fever of unknown origin].

46. Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach.

47. Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis.

48. COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients.

49. Inorganic pyrophosphate is reduced in patients with systemic sclerosis.

50. Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients.

Catalog

Books, media, physical & digital resources